Diana Faini1,2, Aneth Vedastus Kalinjuma1, Andrew Katende1, Gladys Mbwaji1, Dorcas Mnzava1, Amina Nyuri1, Tracy R Glass3,4, Hansjakob Furrer5, Christoph Hatz3,4, David R Boulware6, Emilio Letang1,3,4,7,8. 1. Chronic Diseases Clinic of Ifakara, Ifakara Health Institute, Ifakara, Tanzania. 2. Department of Epidemiology and Biostatistics, Muhimbili University of Health and Allied Sciences (MUHAS), Dar-es-Salaam, Tanzania. 3. Department of Medicine, Swiss Tropical and Public Health Institute, Basel, Switzerland. 4. University of Basel, Basel, Switzerland. 5. Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland. 6. Department of Medicine, University of Minnesota, Minneapolis, MN. 7. Campus Clinic, ISGlobal, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain. 8. Service of Infectious Diseases, Department of Infectious Diseases, Hospital del Mar, Hospital del Mar Research Institute (IMIM), Barcelona, Spain.
Abstract
BACKGROUND: Cryptococcal antigen (CrAg) screening in persons with advanced HIV/AIDS is recommended to prevent death. Implementing CrAg screening only in outpatients may underestimate the true CrAg prevalence and decrease its potential impact. Our previous 12-month survival/retention in CrAg-positive persons not treated with fluconazole was 0%. METHODS: HIV testing was offered to all antiretroviral therapy-naive outpatients and hospitalized patients in Ifakara, Tanzania, followed by laboratory-reflex CrAg screening for CD4 <150 cells/μL. CrAg-positive individuals were offered lumbar punctures, and antifungals were tailored to the presence/absence of meningitis. We assessed the impact on survival and retention-in-care using multivariate Cox-regression models. RESULTS: We screened 560 individuals for CrAg. The median CD4 count was 61 cells/μL (interquartile range 26-103). CrAg prevalence was 6.1% (34/560) among individuals with CD4 ≤150 and 7.5% among ≤100 cells/μL. CrAg prevalence was 2.3-fold higher among hospitalized participants than in outpatients (12% vs 5.3%, P = 0.02). We performed lumbar punctures in 94% (32/34), and 31% (10/34) had cryptococcal meningitis. Mortality did not differ significantly between treated CrAg-positive without meningitis and CrAg-negative individuals (7.3 vs 5.4 deaths per 100 person-years, respectively, P = 0.25). Independent predictors of 6-month death/lost to follow-up were low CD4, cryptococcal meningitis (adjusted hazard ratio 2.76, 95% confidence interval: 1.31 to 5.82), and no antiretroviral therapy initiation (adjusted hazard ratio 3.12, 95% confidence interval: 2.16 to 4.50). CONCLUSIONS: Implementing laboratory-reflex CrAg screening among outpatients and hospitalized individuals resulted in a rapid detection of cryptococcosis and a survival benefit. These results provide a model of a feasible, effective, and scalable CrAg screening and treatment strategy integrated into routine care in sub-Saharan Africa.
BACKGROUND: Cryptococcal antigen (CrAg) screening in persons with advanced HIV/AIDS is recommended to prevent death. Implementing CrAg screening only in outpatients may underestimate the true CrAg prevalence and decrease its potential impact. Our previous 12-month survival/retention in CrAg-positive persons not treated with fluconazole was 0%. METHODS: HIV testing was offered to all antiretroviral therapy-naive outpatients and hospitalized patients in Ifakara, Tanzania, followed by laboratory-reflex CrAg screening for CD4 <150 cells/μL. CrAg-positive individuals were offered lumbar punctures, and antifungals were tailored to the presence/absence of meningitis. We assessed the impact on survival and retention-in-care using multivariate Cox-regression models. RESULTS: We screened 560 individuals for CrAg. The median CD4 count was 61 cells/μL (interquartile range 26-103). CrAg prevalence was 6.1% (34/560) among individuals with CD4 ≤150 and 7.5% among ≤100 cells/μL. CrAg prevalence was 2.3-fold higher among hospitalized participants than in outpatients (12% vs 5.3%, P = 0.02). We performed lumbar punctures in 94% (32/34), and 31% (10/34) had cryptococcal meningitis. Mortality did not differ significantly between treated CrAg-positive without meningitis and CrAg-negative individuals (7.3 vs 5.4 deaths per 100 person-years, respectively, P = 0.25). Independent predictors of 6-month death/lost to follow-up were low CD4, cryptococcal meningitis (adjusted hazard ratio 2.76, 95% confidence interval: 1.31 to 5.82), and no antiretroviral therapy initiation (adjusted hazard ratio 3.12, 95% confidence interval: 2.16 to 4.50). CONCLUSIONS: Implementing laboratory-reflex CrAg screening among outpatients and hospitalized individuals resulted in a rapid detection of cryptococcosis and a survival benefit. These results provide a model of a feasible, effective, and scalable CrAg screening and treatment strategy integrated into routine care in sub-Saharan Africa.
Authors: Emilio Letang; Aneth Vedastus Kalinjuma; Tracy R Glass; Anna Gamell; Herry Mapesi; George Rocky Sikalengo; Lameck Bonaventure Luwanda; Dorcas Mnzava; Alex J Ntamatungiro; Regina Ndaki; Gideon Francis; Fiona Vanobberghen; Hansjakob Furrer; Thomas Klimkait; Ingrid Felger; Marcel Tanner; Christoph Hatz; Maja Weisser; Manuel Battegay Journal: Swiss Med Wkly Date: 2017-07-04 Impact factor: 2.193
Authors: David R Boulware; David B Meya; Conrad Muzoora; Melissa A Rolfes; Katherine Huppler Hullsiek; Abdu Musubire; Kabanda Taseera; Henry W Nabeta; Charlotte Schutz; Darlisha A Williams; Radha Rajasingham; Joshua Rhein; Friedrich Thienemann; Melanie W Lo; Kirsten Nielsen; Tracy L Bergemann; Andrew Kambugu; Yukari C Manabe; Edward N Janoff; Paul R Bohjanen; Graeme Meintjes Journal: N Engl J Med Date: 2014-06-26 Impact factor: 91.245
Authors: Joseph N Jarvis; Stephen D Lawn; Monica Vogt; Nonzwakazi Bangani; Robin Wood; Thomas S Harrison Journal: Clin Infect Dis Date: 2009-04-01 Impact factor: 9.079
Authors: Joan Rugemalila; Venance P Maro; Gibson Kapanda; Arnold J Ndaro; Joseph N Jarvis Journal: Trop Med Int Health Date: 2013-09 Impact factor: 2.622
Authors: Kara N Durski; Karen M Kuntz; Kosuke Yasukawa; Beth A Virnig; David B Meya; David R Boulware Journal: J Acquir Immune Defic Syndr Date: 2013-07-01 Impact factor: 3.731
Authors: Emilio Letang; Matthias C Müller; Alex J Ntamatungiro; Namvua Kimera; Diana Faini; Hansjakob Furrer; Manuel Battegay; Marcel Tanner; Christoph Hatz; David R Boulware; Tracy R Glass Journal: Open Forum Infect Dis Date: 2015-04-02 Impact factor: 3.835
Authors: Nicky Longley; Joseph Nicholas Jarvis; Graeme Meintjes; Andrew Boulle; Anna Cross; Nicola Kelly; Nelesh P Govender; Linda-Gail Bekker; Robin Wood; Thomas S Harrison Journal: Clin Infect Dis Date: 2015-11-12 Impact factor: 9.079
Authors: Ana S Salazar; Matthew R Keller; Margaret A Olsen; Katelin B Nickel; Ige A George; Lindsey Larson; William G Powderly; Andrej Spec Journal: EClinicalMedicine Date: 2020-10-07
Authors: David R Boulware; Elizabeth Nalintya; Radha Rajasingham; Paul Kirumira; Rose Naluyima; Fred Turya; Sylvia Namanda; Morris K Rutakingirwa; Caleb P Skipper; Yofesi Nikweri; Kathy Huppler Hullsiek; Ananta S Bangdiwala; David B Meya Journal: Med Mycol Date: 2020-11-10 Impact factor: 4.076
Authors: Edward Mpoza; Radha Rajasingham; Lillian Tugume; Joshua Rhein; Maria Sarah Nabaggala; Isaac Ssewanyana; Wilson Nyegenye; Grace Esther Kushemererwa; Vivienne Mulema; Julius Kalamya; Charles Kiyaga; Joseph Kabanda; Mina Ssali; David R Boulware; David B Meya Journal: Clin Infect Dis Date: 2020-10-23 Impact factor: 9.079
Authors: Matthew C Fisher; Sarah J Gurr; Christina A Cuomo; David S Blehert; Hailing Jin; Eva H Stukenbrock; Jason E Stajich; Regine Kahmann; Charles Boone; David W Denning; Neil A R Gow; Bruce S Klein; James W Kronstad; Donald C Sheppard; John W Taylor; Gerard D Wright; Joseph Heitman; Arturo Casadevall; Leah E Cowen Journal: mBio Date: 2020-05-05 Impact factor: 7.786